Eighteen commercially available immunoglobulin G (IgG) preparations were evaluated by various methods for anti-cytomegalovirus (CMV) antibodies. The modifications of immunoglobulin G molecules, such as sulfonation, alkylation, and enzyme treatments, resulted in profound reductions in anti-CMV antibody titers. However, after reversion in vitro, sulfonated IgG preparations which have been shown to be reverted in vivo
Eighteen commercially available immunoglobulin G (IgG) preparations were evaluated by various methods for anti-cytomegalovirus (CMV) antibodies. The modifications of immunoglobulin G molecules, such as sulfonation, alkylation, and enzyme treatments, resulted in profound reductions in anti-CMV antibody titers. However, after reversion in vitro, sulfonated IgG preparations which have been shown to be reverted in vivo (Y. Masuho, K. Tomibe, K. Matsuzawa, T. Watanabe, S. Ishimoto, S. Tsunoda, and T. Noguchi, J. Biochem. 79:1377-1379, 1976) restored the anti-CMV antibody titers to levels comparable with those of nonsulfonated IgG preparations. There is no good correlation among the titers tested by different methods. As a method which reflects the biological activities in vivo, the neutralization test in the presence of complement is suitable for the evaluation of IgG preparations.
Recently, it has been shown that human cytomegalovirus (CMV) infections in transplant recipients were successfully prevented or improved by intravenous administration of hyperimmune plasma or immunoglobulin G (IgG) preparations (2-4, 8, 12, 13, 18) . In addition, in murine CMV infections, which are often used as models for human CMV infections, anti-murine CMV antibodies reduced the virus dissemination during the acute phase in immunocompromised mice (16) and protected mice from lethal infections with murine CMV (1). These findings suggested that neutralizing antibody plays an important role in defense against CMV infections. However, the antibody titers of IgG preparations have usually been assayed by methods, such as the complement fixation test (CF), the immunofluorescence test, or enzyme-linked immunosorbent assay (ELISA), which do not always reflect the biological activities of antibodies in vivo. Furthermore, the antibody titers assayed by different methods showed poor correlation with each other (9, 15, 17 nuclei of uninfected human embryonic lung cells. Anti-CMV antibody titer was expressed as cytomegelisa value for the Cytomegelisa kit or as the reciprocal of the final dilution for the N-ELISA which showed 0.200 or more difference in A450 between CMV antigens and controls. CF was carried out by the modified Kolmer method with the nuclear antigens mentioned above on a U-type microplate. IHA titer was determined by a commercially available IHA kit (Cetus Co., Berkeley, Calif.). For IIF, the antigens were prepared by infecting human embryonic lung cells on cover slips with strain AD169 of CMV. After 72 h, the infected cells were washed three times in phosphate-buffered saline, dried, and fixed in acetone at -20°C for 5 min. The infected cells were reacted with serial twofold dilutions (starting from 1:10) of IgG preparations for 30 min at room temperature in a moist chamber and washed three times in phosphate-buffered saline. After reaction with anti-human whole IgG goat serum conjugated with fluorescein isothiocyanate (MBL Inc., Nagoya, Japan) for another 30 min at room temperature, the infected cells were washed three times in phosphate-buffered saline, mounted, and examined for intranuclear fluorescence under an immunofluorescence microscope (model BH-RFL; Olympus, Tokyo, Japan). The antibody titer as determined by IIF was expressed as the reciprocal of the final dilution which showed clear intranuclear fluorescence in the infected cells. Neutralizing antibody titers in the presence or absence of guinea pig complement (at a final dilution of 1:16) were determined by a 50% plaque reduction test as described previously (6) .
Anti-CMV antibody titers determined by various methods are summarized in Table 1 (5, 7, 14) . Although the assays based on these nonbiological activities of antibodies seem to be valuable in monitoring changes in antibody titers in patients, such assays are not reasonable enough to evaluate the antibody titers of IgG preparations which are used for prevention or treatment. Assessment based on biological activities of antibodies which can be expected in vivo is required. With this in mind, we measured the titers of neutralizing antibody in the presence or absence of complement. The neutralizing antibody in the presence of complement is more suitable for the evaluation of IgG preparations, because it reflects more precisely the biological activities of intact and modified IgG molecules. However, the measurement of neutralizing antibody titer requires a complicated procedure and is time consuming; thus, it cannot be performed easily in every laboratory. In place of this measurement, CF using intranuclear antigens permits a substitutive assessment, because it gives a better coefficient of correlation and because the reactions in which not only antibody but also complement participate in vivo would be evaluated. Recently, evaluation of anti-CMV neutralizing antibody in IgG preparations by plaque reduction was similarly attempted by Lewis et al. (9) . The ultimate criterion for any standardized serological test of IgG preparations is correlation with clinical effectiveness. Theoretically, the neutralizing antibody assay should be the most reasonable candidate for such a test.
